130 related articles for article (PubMed ID: 37621175)
1. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls.
Wright K; Mittal A; Gyawali B
Curr Opin Oncol; 2023 Nov; 35(6):513-521. PubMed ID: 37621175
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
Gyawali B; Hey SP; Kesselheim AS
EClinicalMedicine; 2020 Apr; 21():100332. PubMed ID: 32382717
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
[TBL] [Abstract][Full Text] [Related]
5. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
6. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Korn EL; Sachs MC; McShane LM
Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
[TBL] [Abstract][Full Text] [Related]
7. Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.
Ling K; Qin H; Feng Y; Che H; Ding J; Li W
Front Public Health; 2022; 10():1062736. PubMed ID: 36504948
[TBL] [Abstract][Full Text] [Related]
8. Use of Surrogate end points in HTA.
Mangiapane S; Velasco Garrido M
GMS Health Technol Assess; 2009 Aug; 5():Doc12. PubMed ID: 21289899
[TBL] [Abstract][Full Text] [Related]
9. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
10. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
12. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
13. Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
Buyse M; Saad ED; Burzykowski T; Regan MM; Sweeney CS
Oncologist; 2022 Apr; 27(4):266-271. PubMed ID: 35380717
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
Saad ED; Katz A; Hoff PM; Buyse M
Ann Oncol; 2010 Jan; 21(1):7-12. PubMed ID: 19901012
[TBL] [Abstract][Full Text] [Related]
15. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
17. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
19. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class.
Samuel JN; Booth CM; Eisenhauer E; Brundage M; Berry SR; Gyawali B
JAMA Oncol; 2022 Jun; 8(6):879-886. PubMed ID: 35482347
[TBL] [Abstract][Full Text] [Related]
20. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]